Northrop Grumman (NOC) is trading lower Friday as the market continues to digest this week’s first-quarter results and management’s updated investment plans. While the company reaffirmed full-year 2026 guidance, it also lifted planned 2026 capital expenditures to $1.85 billion to support the B-21 production ramp, keeping investor attention on near-term cash-flow and execution risk rather than headline EPS beats. (investor.northropgrumman.com)

Selling pressure was reinforced by incremental analyst caution following the report. Citigroup maintained a Buy rating but cut its price target to $742 (from $807) on April 23, a move that traders treated as confirmation that near-term upside expectations are being reset after the stock’s earlier run. (sahmcapital.com)

In the April 21 release, Northrop reported first-quarter 2026 sales of $9.881 billion and disclosed backlog of $95.6 billion, while reaffirming 2026 guidance for sales of $43.5–$44.0 billion, MTM-adjusted EPS of $27.40–$27.90, and free cash flow of $3.1–$3.5 billion. The debate for investors is whether the higher capex profile and large program ramps—particularly in Aeronautics—can proceed without margin volatility or incremental working-capital drag that would tighten free-cash-flow conversion. (investor.northropgrumman.com)

Near term, traders are likely to focus on management’s ability to keep full-year free cash flow on track while funding accelerated production capacity, and whether future updates provide clearer line-of-sight to improving cash generation as the year progresses. Any additional revisions to capex, program execution commentary, or follow-on analyst target changes could continue to drive outsized moves in NOC as the market recalibrates the risk/reward around the B-21 and other large-scale ramps. (fool.com)